high mobility group nucleosomal binding domain 3 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored HMGN3P1 profile across patient tissues and cancer cell-line models. HMGN3P1 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HMGN3P1 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, HMGN3P1 RNA expression shows 5,611 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight ACC, KIRC, and UCEC as cancer lineages where HMGN3P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGN3P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGN3P1 survival associations across molecular data types. HMGN3P1 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGN3P1 RNA expression–survival associations across cancer types. High HMGN3P1 expression shows unfavorable associations in ACC, CHOL and LUAD, but favorable associations in READ, LUSC and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HMGN3P1 RNA expression.
This table summarizes HMGN3P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HMGN3P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGN3P1 shows lower tumor expression in KIRP, KICH and PAAD and higher tumor expression in KIRC, COAD and BRCA. The KIRC box plot shows higher HMGN3P1 RNA expression in tumor versus normal tissue (log2 FC = +0.386, t-test p < 0.001).
This table shows molecular features associated with HMGN3P1 in patient tissues and cancer cell lines. In patient samples, HMGN3P1 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
